Index

Note: Page numbers in italics – Tables
Page numbers in bold – Figures

AAA, see abdominal aortic aneurysm
abdominal aortic aneurysm (AAA), 86, 87
ADAM study, 91
aneurysm repair, 91
aneurysmal degeneration, 87
branched grafts, 97
Cochrane review, 90
CT, 32, 90
curcumin, 97
doxycycline, 97
dendoleak types, 94, 95
EVAR, 94, 95, 96, 97
fenestrated grafts, 96
hybrid repairs, 97
imaging, 90
inflammatory, 88
intra-arterial angiography, 90
matrix metalloproteinase, 87
mortality rate, 91
MRI, 90
open repair, 34, 92
operative repair, 88
palpable, 88
patient selection, 91
periaortitis, 87
plain radiographs, 89
prevalence, 88
risk factors, 87
rupture, 88
screening, 90
statins, 97
stent graft, 93
tobacco smoking, 87
treatment, 98
UKSAT, 91
ultrasound imaging, 89
vessel layers, 86
abdominal vascular injuries, 179
delayed presentation, 181
mesenteric vessel injuries, 180
operative management, 179
retro-peritoneal haematoma, 179
ABI, see ankle brachial index
above-knee amputation (AKA), 191
ABPI, see ankle : brachial pressure index
activated partial thromboplastin time (aPTT), 225
acute limb ischaemia (ALI), 49, 73
amputation, 54
aetiology, 49
analgesia, 73
anticoagulation, 73
and atherosclerotic disease, 54
causes, 73
classification, 51
compartment syndrome, 56
embolectomy, 74
endovascular treatments, 55
graft occlusion, 54
heparin, 52
intra arterial thrombolysis, 54
investigations, 52
irreversible, 51
mechanical thrombectomy, 76
palliative care, 55
revascularisation, 54
rhabdomyolysis, 56
risk prone area, 49
severity assessment, 51
surgery vs thrombolysis, 75
symptoms, 50
threatened limb, 51, 54
thrombolysis, 54, 75
treatment, 51, 53
unsalvageable limbs, 76
vascular imaging, 52
ADAM, see Aneurysm Detection and Management
Ambulatory Venous Pressure (AVP), 210
amputation, 183
aetiology, 185
Chopart, 189
epidemiology, 184
level, 68
lower limb, 191
pain, 193
pain cause, 192
postoperative complications, 191
preoperative assessment, 186
primary, 68
prosthetics, 193
secondary, 68
surgical principles, 188
toe, 189
types, 186
upper limb, 191
anaerobic threshold (AT), 274
anastomotic techniques, 77
aneurysm
aneurysmal degeneration, 87
mycotic, 87, 241
surgical management, 104,
see also pseudoaneurysm
Aneurysm Detection and Management (ADAM), 91
aneurysmal tissue, 99
angiplasty, 78
aortic, 81
arterial dissection, 80
arterial puncture site
haemorrhage, 79
arterial rupture, 80
complications, 80
distal embolization, 80
iliac artery, 81
procedure, 79
subintimal, 79
ankle brachial index (ABI), 37
ankle level amputation, 190
ankle : brachial pressure index (ABPI), 60
measurement, 60
pole test, 61

© in this web service Cambridge University Press www.cambridge.org
antiphospholipid syndrome, 221–4
anti-platelet agents
aspirin, 277
clopidogrel, 277
anti-platelet therapy, 45
clopidogrel vs. aspirin, 45
guidelines, 46
aortic angioplasty, 81
aortic dissection, 108
acute, 110
associated factors, 108
complications, 113
Debakey classification, 110, 111
diagnosis, 110
end-organ ischaemia, 109
factors associated, 109
graft replacement, 112
intimal disruption, 109
intramural haematoma, 109
lumen creation, 108
management, 111
presentation, 110
Stanford classification, 110, 111
symptoms, 110
tearing, 109
type A, 112
type B chronic, 113
type B complicated, 113
type B uncomplicated, 112
aortic stent graft infection, 236
aorto-iliac bypass, 77
aPTT, see activated partial thromboplastin time.
arterial claudication causes, 26
dissection, 80
puncture site haemorrhage, 79, 80
repair, 175
rupture, 80
vs. venous claudication, 29
arterial occlusion 50
arterial TOS (ATOS), 149
treatment, 150,
see also neurogenic TOS, venous TOS
arteriography
contraindications, 158
arteriovenous fistula (AVF), 9
and cardiac failure, 10
complications, 11
location, 10
pulsatility in, 10
risk indicators, 10
arterio-venous malformations (AVMs), 21
aspiration thrombectomy, 55
aspirin, 64, 277
AT, see anaerobic threshold
ATOS, see arterial TOS
auscultation, 60
autonomic neuropathy, 69
AVF, see arteriovenous fistula
AVMs, see arterio-venous malformations
AVP, see Ambulatory Venous Pressure
axillo-bifemoral grafts, 77, 78
β-adrenergic blocking agents
Baker's cyst, 3
BASIL, see Bypass versus Angioplasty in Severe Ischaemia of the Leg
β-blockers, see β-adrenergic blocking agents
BD, see Bechaisi's disease
Bechaisi's disease (BD), 266
investigation, 266
management, 267
presentation, 266
below knee stenting, 82
below-knee amputation (BKA), 190
β-Blockers, 278
bilateral carotid surgery
preoperative assessment, 16,
see also carotid body tumour
Biothesiometer, 14
BKA, see below-knee amputation
blue toe syndrome, 100
brainstem death tests, 307
Brainstem death tests, 308
branched grafts, 97
bruit, 60
Buerger's disease, 18, 264
diagnostic criteria, 18, 265
features, 265
investigations, 265
management, 19, 266
peripheral angiogram, 19
presentation, 265
risk population, 18
symptoms, 18
vasculitides types, 19
'buffalo-hump', 198
buttock claudication, 59
bypass graft stenoses, 67
veins, 66
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)
angioplasty first strategy, 73
surgery first strategy, 73
survival rate, 73
calcineurin inhibitor, 314
CAD, see coronary artery disease, cystic adventitial disease
calcium channel blockers, 260
calf claudication, 59
calf muscle pump, 29,
see also chronic venous insufficient (CVI)
cardiac failure, 283
contractility, 283
function maximization, 283
output estimation methods, 283
oxygen delivery, 282
vasodilatation, 283
Cardiac Risk Index, 273
cardiopulmonary exercise testing (CPX), 102, 274
cardiovascular events
aspirin, 64
clopidogrel, 64
dl life style modification, 64
ramapril, 64
carotid aneurysms, 134
investigations, 135
operative strategies, 135
prevalence, 134
prognosis, 135
pulsatile neck mass, 135
carotid artery injury, 177
blunt injury, 179
classification, 177
diagnosis, 177
management, 178
carotid artery stenting (CAS), 140
carotid body tumour (CBT), 5, 135
causes, 136
characteristics, 6
cross-sectional imaging, 136
CT/MR findings, 6
diagnosis, 6
duplex ultrasound, 136
### Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>endovascular interventions, 7 features, 136</td>
</tr>
<tr>
<td>7</td>
<td>intra-arteral angiography, 7 location, 6</td>
</tr>
<tr>
<td>6</td>
<td>perioperative bleeding reduction, 136</td>
</tr>
<tr>
<td>6</td>
<td>preop assessment, 6</td>
</tr>
<tr>
<td>6</td>
<td>prognosis, 136</td>
</tr>
<tr>
<td>6</td>
<td>resection treatment, 136</td>
</tr>
<tr>
<td>6</td>
<td>Shamblin classification, 6 symptoms, 6</td>
</tr>
<tr>
<td>7</td>
<td>carotid dissection (CD), 131 causes, 131</td>
</tr>
<tr>
<td>132</td>
<td>carotid endarterectomy (CEA), 138</td>
</tr>
<tr>
<td>140</td>
<td>benifits, 140</td>
</tr>
<tr>
<td>16</td>
<td>carotid shunt, 16</td>
</tr>
<tr>
<td>17</td>
<td>cerebral perfusion, 17</td>
</tr>
<tr>
<td>15</td>
<td>complications, 15</td>
</tr>
<tr>
<td>16</td>
<td>cranial nerves, 16</td>
</tr>
<tr>
<td>140</td>
<td>criteria for surgery, 140</td>
</tr>
<tr>
<td>16</td>
<td>GALA trial, 16</td>
</tr>
<tr>
<td>142</td>
<td>patient management, 140</td>
</tr>
<tr>
<td>17</td>
<td>post-op CVE, 17</td>
</tr>
<tr>
<td>16</td>
<td>risks, 16</td>
</tr>
<tr>
<td>140</td>
<td>stroke reduction, 140</td>
</tr>
<tr>
<td>140</td>
<td>treatment speed, 140</td>
</tr>
<tr>
<td>212</td>
<td>carotid patching, 16</td>
</tr>
<tr>
<td>62</td>
<td>colour flow duplex (CFD), 62</td>
</tr>
<tr>
<td>28</td>
<td>chronic venous ulceration, 28</td>
</tr>
<tr>
<td>215</td>
<td>congenital lymphoedema, 195</td>
</tr>
<tr>
<td>242</td>
<td>congenital vascular malformations (CVMs), 242</td>
</tr>
<tr>
<td>160</td>
<td>endarterectomy, 160</td>
</tr>
<tr>
<td>156</td>
<td>chronic mesenteric ischaemia (CMI), 156</td>
</tr>
<tr>
<td>245</td>
<td>Mulliken classification, 245</td>
</tr>
<tr>
<td>247</td>
<td>classification, 247</td>
</tr>
<tr>
<td>246</td>
<td>diagnosis, 247</td>
</tr>
<tr>
<td>245</td>
<td>differential diagnosis, 245</td>
</tr>
<tr>
<td>216</td>
<td>aetiology, 215, 216</td>
</tr>
<tr>
<td>77</td>
<td>ALARA principle, 83</td>
</tr>
<tr>
<td>83</td>
<td>anastomosis, 77</td>
</tr>
<tr>
<td>77</td>
<td>anastomotic techniques, 77</td>
</tr>
<tr>
<td>81</td>
<td>angioplasty, 79, 81</td>
</tr>
<tr>
<td>80</td>
<td>angioplasty complications, 80</td>
</tr>
<tr>
<td>77</td>
<td>aorto-iliac bypass, 77</td>
</tr>
<tr>
<td>77</td>
<td>autologous grafts, 77</td>
</tr>
<tr>
<td>77</td>
<td>axillo-bifemoral grafts, 77</td>
</tr>
<tr>
<td>82</td>
<td>below knee stenting, 82</td>
</tr>
<tr>
<td>83</td>
<td>considerations for endovascular procedures, 84</td>
</tr>
<tr>
<td>76</td>
<td>endarterectomy, 76</td>
</tr>
<tr>
<td>83</td>
<td>endovascular theatre, 83</td>
</tr>
<tr>
<td>83</td>
<td>femoral-femoral crossover graft, 77</td>
</tr>
<tr>
<td>77</td>
<td>femorono-distal bypass, 78</td>
</tr>
<tr>
<td>77</td>
<td>femoro-popliteal bypass, 77</td>
</tr>
<tr>
<td>81</td>
<td>hybrid procedures, 83</td>
</tr>
<tr>
<td>76</td>
<td>imaging techniques, 76</td>
</tr>
<tr>
<td>76</td>
<td>lesion prioritisation, 76</td>
</tr>
<tr>
<td>77</td>
<td>LSV, 77</td>
</tr>
<tr>
<td>77</td>
<td>prosthetic grafts, 77</td>
</tr>
<tr>
<td>83</td>
<td>required treatments, 84</td>
</tr>
<tr>
<td>83</td>
<td>restenosis, 83</td>
</tr>
<tr>
<td>81</td>
<td>SFA stenting, 81</td>
</tr>
<tr>
<td>83</td>
<td>stent graft, 83</td>
</tr>
<tr>
<td>76</td>
<td>surgical bypass, 76</td>
</tr>
<tr>
<td>84</td>
<td>TASC guidelines, 84</td>
</tr>
<tr>
<td>84</td>
<td>trauma, 84</td>
</tr>
<tr>
<td>84</td>
<td>upper limb revascularisation, 84</td>
</tr>
<tr>
<td>158</td>
<td>transaortic endarterectomy, 159</td>
</tr>
<tr>
<td>28</td>
<td>chronic venous insufficiency (CVI), 28</td>
</tr>
<tr>
<td>215</td>
<td>aetiology, 215</td>
</tr>
<tr>
<td>216</td>
<td>clinical features, 207</td>
</tr>
<tr>
<td>215</td>
<td>epidemiology, 215</td>
</tr>
<tr>
<td>217</td>
<td>treatment, 217</td>
</tr>
<tr>
<td>28</td>
<td>venous skin changes, 28</td>
</tr>
<tr>
<td>208</td>
<td>chronic venous ulceration, 28</td>
</tr>
<tr>
<td>9</td>
<td>Cimino Brescia fistula, 9</td>
</tr>
<tr>
<td>56</td>
<td>clopidogrel, 64, 277</td>
</tr>
<tr>
<td>243</td>
<td>cockcroft-gault formula, 302</td>
</tr>
<tr>
<td>153</td>
<td>colorimetry, 153</td>
</tr>
<tr>
<td>62</td>
<td>compartment syndrome, 56</td>
</tr>
<tr>
<td>56</td>
<td>fasciotomy, 56, 168</td>
</tr>
<tr>
<td>28</td>
<td>chronic venous insufficiency (CVI), 28</td>
</tr>
<tr>
<td>31</td>
<td>hosiery, 31</td>
</tr>
<tr>
<td>31</td>
<td>stocking classes, 31</td>
</tr>
<tr>
<td>23</td>
<td>therapy, 23</td>
</tr>
<tr>
<td>195</td>
<td>congenital lymphoedema, 195</td>
</tr>
<tr>
<td>242</td>
<td>congenital vascular malformations (CVMs), 242</td>
</tr>
<tr>
<td>247</td>
<td>classification, 247</td>
</tr>
<tr>
<td>246</td>
<td>diagnosis, 247</td>
</tr>
<tr>
<td>245</td>
<td>differential diagnosis, 245</td>
</tr>
<tr>
<td>251</td>
<td>endovascular treatment, 251</td>
</tr>
<tr>
<td>243</td>
<td>eponymous syndromes, 243</td>
</tr>
<tr>
<td>244</td>
<td>extra-truncular, 244</td>
</tr>
<tr>
<td>250</td>
<td>Hamburg classification, 244</td>
</tr>
<tr>
<td>248</td>
<td>indications for intervention, 248</td>
</tr>
<tr>
<td>246</td>
<td>investigation, 246</td>
</tr>
<tr>
<td>247</td>
<td>MRI, 247</td>
</tr>
<tr>
<td>245</td>
<td>Mulliken classification, 245</td>
</tr>
<tr>
<td>314</td>
<td>CD4 cells, 314, see also major histocompatibility complex</td>
</tr>
<tr>
<td>212</td>
<td>RFA, 212</td>
</tr>
<tr>
<td>136</td>
<td>cavernous haemangiomas, 20</td>
</tr>
<tr>
<td>106</td>
<td>cerebrospinal fluid (CSF), 106</td>
</tr>
<tr>
<td>194</td>
<td>chronic mesenteric ischaemia (CMI), 156</td>
</tr>
<tr>
<td>166</td>
<td>endovascular treatment, 160</td>
</tr>
<tr>
<td>217</td>
<td>treatment, 217</td>
</tr>
<tr>
<td>208</td>
<td>venous skin changes, 28</td>
</tr>
<tr>
<td>208</td>
<td>chronic venous ulceration, 28</td>
</tr>
</tbody>
</table>

Cambridge University Press
978-0-521-13352-4 - Postgraduate Vascular Surgery: The Candidate’s Guide to the FRCS
Edited by Vish Bhattacharya and Gerard Stansby

More information
connective tissue disorders, 267
Ehlers-Danlos (ED) syndrome, 270
Loeys-Dietz (LD) syndrome, 269, 270
Marfan's syndrome, 268
Continuous Positive Airway Pressure (CPAP), 281
Continuous Veno-Venous Haemofiltration (CVVH), 285
contrast induced nephropathy (CIN), 284
balloon expandable stents, 81
carbon dioxide, 80
N-acetylcysteine (NAC), 80
stent, 81
coronary artery disease (CAD)
ACEI and ATII, 278
acute case management, 279
anti-platelet agents, 277
β blockers, 278
cardiomyopathies, 277
drug therapy, 278
oral anticoagulants, 278
preoperative investigations, 272, 275
scoring systems for surgery, 273, 274
statins, 278
surgery risk assessment, 273
coronary stents, 276
costocutaneous space, 146
covered stents, see stent graft
CPAP, see Continuous Positive Airway Pressure
cranial arteritis, 132
critical care, 279
cardiac failure, 283
levels, 279, 280
nutrition, 286
renal failure, 285
respiratory failure, 282
sepsis, 287
critical illness, 286
critical limb ischaemia
revascularization, 185
critical limb ischaemia (CLI), 58, 66
amputation, 68
BASIL study, 67
cardiocerebrovascular risk, 66
diagnosis, 66
Duplex ultrasound surveillance, 67
infra-geniculate bypass, 66
prevalence, 58
surgical bypass, 67
trans-luminal angioplasty, 66
vein bypass graft, 67
CSE, see cerebrospinal fluid curcumin, 97
CVE, see cerebrovascular event
CVI, see chronic venous insufficiency
CVMs, see congenital vascular malformations
CVVH, see Continuous Veno-Venous Haemofiltration
cystic ddventitial disease (CAD), 25
cystic hygroma, 21
dabigatran, 226
d-Dimer testing, 223
death, 307
Debakey classification, 111
disseotions types, 110
dep vein thrombosis (DVT), 220–2, 221–4, 223–11
clinical features, 221–5
diagnostic evaluation, 223
factor Xa inhibitors, 226
IVC filters, 227
LMWH treatment, 226–7
patient assessment, 224
prophylaxis, 224–6
PTS, 227
in right popliteal vein, 223–10
risk assessment, 221–5
risk factors, 222
thrombolysis, 227–10
UFH treatment, 224
Wells clinical score, 222
descending thoracic aortic aneurysm (DTAA)
blue toe syndrome, 100
branched and fenestrated grafts, 104
causes, 99
complication reduction, 104
105, 106
complications and adjuncts, 104
CPX testing, 102
CT angiogram, 100
endovascular approach, 104
GI tract risk reduction, 106
intraoperative heparin, 104
involving aortic arch, 103
left-sided thoracotomy, 103
management, 101
pre-operative assessment, 102
renal and hepatic function, 102
stress echocardiography, 101
diabetes, 276
HbA1C and macrovascular events, 47
diabetic foot, 13, 69, 189
critical assessment, 13
clinical features, 68
cosequences, 185
infection level, 70
limb loss, 13
management, 14, 70
negative pressure wound therapy, 70
diabetic neuropathy, 14
Biothesiometer, 14
testing, 14
diabetic vascular disease
automonic neuropathy, 69
diabetic foot management, 70
foot complications, 70
ischaemia, 70
motor neuropathy, 69
neuropathy, 69
prevalence, 68
sensory neuropathy, 69
distal embolisation, 100
distal endoleak, 94
distal ischaemia, 173
arm inspection, 9
popliteal aneurysms in, 3
see also limb ischaemia
doxycycline, 97
Drumond marginal artery, 165
DTAA, see descending thoracic aortic aneurysm
duplex Doppler ultrasonography (DUS), 124
DUS, see duplex Doppler ultrasonography
DVT, see deep venous thrombosis
dyslipidaemia, 41
blood sampling, 42
recommendations, 43
statin therapy, 42
eczema, 208
ED syndrome, see Ehlers-Danlos (ED) syndrome
effort thrombosis, see Paget-Schroetter syndrome
Ehlers-Danlos (ED) syndrome, 269
investigation, 270
presentation, 269
elephant trunk procedure, 112
Elevated Arm Stress Test (EAST), see Roos test
embolectomy, 74
brachial artery bifurcation, 54
at femoral bifurcation, 53
femoral bypass, 54
at femoral popliteal bifurcation, 53
post-op care, 54
thrombotic occlusion resistant, 75
emboli
distal embolization, 75, 80
saddle, 50
supra-inguinal occlusive emboli, 74
symptomatic distal embolisation, 124, see also arterial occlusion, embolectomy, femoral embolectomy, graft occlusion
endarterectomy, 76
endofibrosis, 25
endoleak, 32, 33, 94
type I, 94
type II, 95
type III, 95
type IV, 95
type V, 95
end-organ ischaemia, 109
endotension, see also endoleak
endovascular aneurysm repair (EVAR), 31
aortic morphology, 93
benefit, 97
branched grafts, 97
CT scans, 93
fabric grafts, 92
fenestrated grafts, 96
follow-ups, 95
hybrid repairs, 97
infection risk reduction, 93
proximal neck, 93
risks, 34
trial I, 96
trial II, 96
endovascular treatment, 5, 7, 161, 162
see also percutaneous transluminal angioplasty and stenting
eponymous syndromes, 243, 244
EVAR, see endovascular aneurysm repair
excision, 154
FAA, see femoral artery aneurysm
Factor Xa inhibitors, 226
FApA, see femoral artery pseudoaneurysms
FAPs, see femoral anastomotic pseudoaneurysm
fasciectomy, 56
indications, 55, 176
see also compartment syndrome
femoral anastomotic pseudoaneurysms (FAPs), 7
aortobifemoral surgery consequence, 8
bilateral femoral artery aneurysms, 8
diagnosis, 8
factors inducing, 9
indicators for treatment, 9
surgical repair, 9
symptoms, 7, 8
femoral artery aneurysm (FAA), 123
acute thrombosis, 124
chronic thrombosis, 124
classification, 124
conservative management, 125
DUS, 124
interposition graft, 125
occurrence, 123
pathophysiological conditions, 123
perioperative mortality rates, 125
symptomatic distal embolisation, 124
symptoms, 124
femoral artery pseudoaneurysms (FApA), 126
DUS evaluation, 127
investigation, 126
post-catheterisation, 126
symptoms, 126
treatments, 127, see also profunda femoris artery aneurysms
femoral embolectomy at femoral aortic bifurcation, 53
preparation, 53
thrombosed popliteal artery aneurysm, 54
femoral-femoral crossover graft, 77
femoro-distal bypass, 78
femoro-popliteal bypass, 77
fenestrated grafts, 96
fibrillin, 267
fibrin cuff hypothesis, 216
fibromuscular dysplasia (FMD), 130, 131
carotid/vertebral angioplasty, 131
causes, 130
investigation, 131
prognosis, 131
Fibromuscular dysplasia (FMD), 25
FMD, see fibromuscular dysplasia
foam sclerotherapy, 211
fondaparinux, 226
see also heparin
foot ulceration, see diabetic foot
FRCS examination, 1–2
fusiform aneurysms, 117
gangrene, 185
GCA, see giant cell arteritis
Ghent diagnostic criteria, 268
giant cell arteritis (GCA), 132, 263
cerebrovascular events, 132
cranial arteritis, 132
high dose steroid therapy, 133
investigation, 133, 264
large vessel vasculitis, 132
management, 264
pathology, 132
presentation, 264
prognosis, 133
systemic inflammatory syndrome, 132,
giant cell arteritis (GCA) (cont.)
see also temporal arteritis

glomus vagale tumours, 136

graft
arm vein, 118
autologous vein, 118
composite-sequential, 119
great saphenous vein, 174
inlay grafting, 118
long saphenous vein, 77

graft infection
aortic stent graft, 233
clinical presentation, 231
extra-anatomic bypass, 234
grade III infection, 230
infected aortic grafts, 236
infected carotid patches, 237
infected peripheral grafts, 238
in-situ vein graft, 233
investigations, 233
mycotic aneurysm, 241

graft occlusion
treatment, 54, see also arterial occlusion, emboli
graft rejection, 313
mechanism, 314,
see also organ transplantation

haemangioma, 20
infantile, 243
haematoma, 89
haematoma effects, 16
'halo sign', 264
Hamburger classification, 244
Hand Held Doppler (HHHD), 27
'helper' cells, see CD4 cells
heparin, 225
in ALI, 73
CD, 132
in clinical practice, 220
intraoperative dose, 92, 104
ischaemic colitis, 168
and mechanical heart valves, 278
pericatheter thrombus, 74
in post-op care, 54
and sclerotherapy, 182
in vascular repair, 175,
see also thrombolyis.
heparin-induced
thrombocytopenia (HIT), 226–7
HHD, see Hand Held Doppler
HIT, see heparin-induced thrombocytopenia.
Homan's operation, 202
Homan's sign, 221
homocysteine, 47
hyperhomocystinemia, 48
recommendations, 48
hyperhidrosis, 152
aluminium chloride hexahydrate, 153
botulinum toxin A treatment, 153
botulinum treatment side-effects, 154
causes, 152
chemical sympathectomy, 155
colorimetry, 153
compensatory sweating, 154
diagnosis, 153
glycopyrrhinate treatment, 153
iontophoresis, 153
primary, 152
secondary, 152
surgery, 154
sympathectomy, 154, 155
symptoms, 152
hyperkalaemia
effect on revascularisation, 76
treatment, 285, see also renal failure
hypertension
ACE inhibitor, 44
B-Blockers, 45
recommnendations, 45
treatment guidelines, 44
venous etiology, 29
hyphenweb varices, 208
hypoglycaemia, 15
iatrogenic vascular injuries, 128
ICDs, see implantable cardiac defibrillators
iliac artery angioplasty, 81
endoaortic stenting, 81
left common iliac artery occlusion, 82
right sided stent, 82
stent placement, 81
iliac vein injuries, 180
iloprost, 260
immunosuppressive agents, 314, 315
malignant growth, 300,
see also graft rejection
implantable cardiac defibrillators (ICDs), 276,
see also permanent pacemakers
infantile haemangioma, 243
infection
femoral pseudoneuropathies, 240
postoperative, 230
inotropic agents, positive, 283
INR, see international normalized ratio.
intermittent claudication, 58, 59
amputation, 184
angioplasty trials vs. exercise, 66
claudication distances, 59
nerve root irritation, 61
non-atherosclerotic cause, 61
spinal canal stenosis, 61
surgical reconstruction, 66
international normalized ratio (INR), 225
International Registry of Acute Aortic Dissection (IRAD), 112
interscalene triangle, 146
intestinal angina, 157
intimal disruption, 109
intimal fibroplasia, 130
intra-arterial angiography, 90
iontophoresis, 153
IRAD, see International Registry of Acute Aortic Dissection
ischaemia, 49
reversibly ischaemic, 51
signs, 60
thrombosis, 51,
see also compartment syndrome
rhabdomyolysis
ischaemic colitis, 164
aetiology, 165
anatomical factors, 166
clinical features, 166
diagnosis, 166
etymology, 164
investigations, 168
management, 168
in mucosa, 165
pathophysiology, 165
post aortic, 169
prevention, 170
risk factors, 169
"Ischemic monomelic neuropathy", 296
IVC injuries, 180
kidney transplantation, see renal transplantation
Klippel-Trenaunay syndrome, 243
Klippel-Trénaunay syndrome (KTS), 21
non surgical options, 23
pathological components, 22
surgical options, 23
varicose veins, 22
varicosities distribution, 22
venous system, 22
KTS, see Klippel-Trénaunay syndrome
large vessel vasculitis, 132
laryngeal nerve, 15
LD syndrome, see Loeys-Dietz (LD) syndrome
limb distal vessel injury, 176
limb ischaemia, 173
limb vascular injury assessment, 173, 174
investigations, 174
lipidema, 203
lipodermatosclerosis, 208
liposuction, 154, 202
liver disease, alcohol-induced, 299
liver transplantation (LT), 300
disease specific indications, 299
operative technique, 310
postoperative complications, 312
L-lactate, 167
LMWH, see low molecular weight heparin.
Loeys-Dietz (LD) syndrome, 268
investigations, 270
management, 270
presentations, 269
long saphenous vein (LSV), 77
low molecular weight heparin (LMWH), 224
lower limb amputation, 191
AKA, 191
ankle level amputation, 190
BKA, 190
decision making, 186
hindquarter amputation, 191
mid-foot amputation, 189
preoperative checklist, 187
ray amputation, 189
through-knee amputation, 190
toe amputation, 189
transmetatarsal amputation, 189
lower limb swelling
differential diagnosis, 196
DVT; 198
LSV, see long saphenous vein
LT, see liver transplantation
lung disease, see pulmonary diseases
lymphangioma
circumscriptum, 21
lymphangioscintigraphy, 12, 199
lymphoedema, 11, 195
bypass procedures, 203
causes, 197
Charles’ procedure, 202
classification, 11, 12, 196
compression therapy, 201
computed tomography, 199
decongestive physiotherapy, 201
diagnosis, 198
drugs, 202
of foot, 12
Homan’s operation, 202
infection prevention, 202
investigations, 200
of leg, 198
liposuction, 202
lymphangioscintigraphy, 199
lymphatic drainage, 200
management, 200
MR features, 200
MRI findings, 12
pathophysiology, 197
secondary causes, 12
surgical procedures, 13
symptoms, 11
treatment, 200
magnetic resonance angiography (MRA), 63
chronic limb ischaemia, 76
chronic mesenteric ischaemia, 158
MRA, 90
major histocompatibility complex (MHC), 314
magnesium, 284
Marfan syndrome, 267
investigation, 268
management, 268
presentation, 267
mechanical thrombectomy, 55
ALI, 76, see also thrombolysis
mediastinal dysplasia, 130
mesenteric vessel injuries, 180
MHC, see major histocompatibility complex
mid-foot amputation, 189
Milroy’s disease, see congenital lymphoedema
MOPS, see Multiple Organ Dysfunction Syndrome motor neuropathy, 69
MRA, see magnetic resonance angiography
MRI, see magnetic resonance imaging
Multiple Organ Dysfunction Syndrome (MODS), 279
mycotic aneurysm, 236, 241
National institute of clinical excellence (NICE)
neonatal haemangioma, 243
neovascularisation, 213
nerve root irritation, 61
neurogenic TOS (NTOS), 148
Adson test, 148
botulinum chemodenervation, 150
paraesthesia, 148
Roos test, 148
surgical treatment, 150,
see also arterial TOS, venous TOS
neuropathic foot ulcer, 69
neuropathy autonomic, 69
motor, 69
sensory, 69
NICE see National institute of clinical excellence

© in this web service Cambridge University Press
www.cambridge.org
nifedipine, 260
NTOS, see neurogenic TOS
obesity, 275
obstructive pulmonary diseases, 275
occlusive lesions, 158
open aneurysm repair, 92
oral anticoagulants, 278
organ allocation
ethical principles, 304, 307
factors considered, 306
system of allocation, 304, see also organ transplantation
organ donation, 307
contraindications, 308
death conformation, 307
donor categories, 308
donor operation, 309
ethics, 307
organ failure, 280
cardiac failure, 283
indicators, 281
renal failure, 285
respiratory failure, 282
therapeutic measures, 280
organ procurement, 309
organ transplantation, 305
life expectancy, 315
postoperative complications, 311
solid, 298
osteomyelitis
diagnostic imaging, 15
and graft infection, 231
x-ray, 70
PAA, see popliteal artery aneurysms
PAD, see peripheral arterial disease
Paget-Schroetter syndrome, 149
pancreas transplantation, 303
operative technique, 310
postoperative complications, 313, see also renal transplantation
paragangliomas, 5
patient type, 5
treatment, 5
paraplegia risk reduction, 106
Parkes-Weber syndrome, 23, 243
PAs, see popliteal aneurysms
PCI, see Percutaneous Coronary Interventions.
PE, see pulmonary embolism.
Percutaneous Coronary Interventions (PCI), 277
percutaneous transluminal angioplasty and stenting (PTA/Stent), 161, 163
perforator surgery, 213
peripheral arterial disease (PAD), 37
ABI predictor, 38
ABPI measurement, 60
ACE inhibitor, 44, 45
anti-platelet therapy, 45
aspirin resistance, 46
auscultation, 60
B-Blockers, 45
cardiovascular events, 38
cardiovascular risk management, 59, 60, 65
CDF ultrasound scanning, 62
cholesterol reduction, 64
circulation examination, 60
claudication, 58, 59, 60
clopidogrel vs aspirin, 45
CT angiogram, 62
CV risk, 59
diabetes, 46, 64
differential diagnosis, 61
dyslipidaemia, 44
hazard ratios, 42
homocysteine, 48
hypertension, 45, 64
Kaplan Meier survival curves, 40
life style modification, 47
MRA, 63
platelet activation, 46
pole test, 61
prevalence, 58
pulse palpation, 60
risk factors, 37, 38
simvastatin therapy, 42
smoking, 40, 64
spinal canal claudication, 59
survival rate, 37
walking, 61, 66
peripheral vasodilators, 260
permanent pacemakers (PPM), 276
permissive hypercapnia, 282
PFAa, see profunda femoris artery aneurysms
phlebectomy, 213
phlebmasia cerulea dolens, 221–5
phlebmasia alba dolens, 221–5
plethysmography, 210
Polyarteritis nodosa, 19
popliteal aneurysms (PAs), 3, 4
dovascular treatment, 5
indications for treatment, 5
ischaemic complications, 5
need for thrombolysis, 5
symptoms, 4
popliteal artery, 4
accessing, 4
thrombosis, 54, see also popliteal aneurysms
popliteal artery aneurysms (PAA), 115
bilateral, 117
causes, 115
clopidogrel, 121
complication, 116
embolectomy, 120
doovascular repair, 121
doovascular treatment results, 121
fusiform aneurysms, 117
graft repair, 119
intervention, 117
investigation, 116
ligation, 118
limb salvage, 120
posterior approach, 118, 119
preoperative lysis, 120
presentation, 116
pulsatile mass, 116
risk factors, 117, 121
rupture, 116
saccular aneurysms, 117
symptoms, 116
thrombolysis, 120
treatment, 117, 119
popliteal entrapment syndrome, 23
classifications, 25
clinical examination, 24
compression causes, 24
embryological factors, 24
portal vein injuries, 180
postoperative death risk factors, 275
post operative infection, 230
antibiotic prophylaxis, 231
causative organisms, 230
prevention, 231
<table>
<thead>
<tr>
<th>Index</th>
<th>325</th>
</tr>
</thead>
<tbody>
<tr>
<td>risk factors, 231, see also graft infection</td>
<td></td>
</tr>
<tr>
<td>postphlebitic syndrome, 218</td>
<td></td>
</tr>
<tr>
<td>post-thrombotic syndrome (PTS), 227</td>
<td></td>
</tr>
<tr>
<td>post-thrombotic syndrome (PTS), 228, see also postphlebitic syndrome</td>
<td></td>
</tr>
<tr>
<td>&quot;potato tumour&quot;, see carotid body tumour (CBT)</td>
<td></td>
</tr>
<tr>
<td>PPM, see permanent pacemakers</td>
<td></td>
</tr>
<tr>
<td>primary Raynaud's disease (RD), 255</td>
<td></td>
</tr>
<tr>
<td>profunda femoris artery aneurysms (PFAa), 126 treatment aim, 126</td>
<td></td>
</tr>
<tr>
<td>prophylaxis antibiotic, 231</td>
<td></td>
</tr>
<tr>
<td>prosthetics, 193</td>
<td></td>
</tr>
<tr>
<td>Proteus syndrome, 23</td>
<td></td>
</tr>
<tr>
<td>proximal endoleak, 94</td>
<td></td>
</tr>
<tr>
<td>pseudaneurysm infected femoral, 240</td>
<td></td>
</tr>
<tr>
<td>mycotic, 127</td>
<td></td>
</tr>
<tr>
<td>post-catherisation, 126</td>
<td></td>
</tr>
<tr>
<td>predisposing factors, 127</td>
<td></td>
</tr>
<tr>
<td>pseudoxanthoma elasticum (PXE), 26, 270 investigations, 271 management, 271 presentation, 270</td>
<td></td>
</tr>
<tr>
<td>PTA/Stent, see percutaneous transluminal angioplasty and stenting</td>
<td></td>
</tr>
<tr>
<td>PTS, see post-thrombotic syndrome</td>
<td></td>
</tr>
<tr>
<td>pulmonary diseases, 275</td>
<td></td>
</tr>
<tr>
<td>pulmonary embolism (PE), 220</td>
<td></td>
</tr>
<tr>
<td>&quot;Pulseless disease&quot;, see Takayasu arteritis</td>
<td></td>
</tr>
<tr>
<td>PXE, see pseudoxanthoma elasticum</td>
<td></td>
</tr>
<tr>
<td>radiation arteritis features, 129 investigation, 130 pathology, 129 treatment, 130 ray amputation, 189</td>
<td></td>
</tr>
<tr>
<td>Raynaud's phenomenon (RP), 254, 255 blood flow assessment techniques, 259 epidemiology, 255 genetic predisposition, 258</td>
<td></td>
</tr>
<tr>
<td>haemodynamic changes, 256 immune regulation, 258 investigations, 259 management, 261 mechanical damage, 258 neurogenic response, 256 organs affected, 255 presentation, 254, 258 triggering factors, 255, see also Takayasu arteritis</td>
<td></td>
</tr>
<tr>
<td>RD, see primary Raynaud's disease</td>
<td></td>
</tr>
<tr>
<td>REACH, see Reduction of Atherothrombosis for Continued Health</td>
<td></td>
</tr>
<tr>
<td>recombinant tissue plasminogen activator (rTPA), 74</td>
<td></td>
</tr>
<tr>
<td>Reduction of Atherothrombosis for Continued Health (REACH), 37</td>
<td></td>
</tr>
<tr>
<td>renal failure, 285 access placement, 289 acute, 284 causes, 283 CIN, 284 management, 284 vein injuries, 180</td>
<td></td>
</tr>
<tr>
<td>renal replacement therapy (RRT), 289</td>
<td></td>
</tr>
<tr>
<td>renal transplantation contraindications, 303 indications for, 301 live donation, 301 operative technique, 310 postoperative complications, 313 recurring diseases, 302 respiratory failure, 282 arterial blood gas (ABG) analysis, 280</td>
<td></td>
</tr>
<tr>
<td>CPAP, 281 oxygen face masks, 281 permissive hypercapnia, 282 positive pressure ventilation, 282</td>
<td></td>
</tr>
<tr>
<td>restenosis, 83 external beam radiotherapy, 83 stent graft effect, 83 restrictive pulmonary diseases, 275</td>
<td></td>
</tr>
<tr>
<td>reticular varices, 208 retrograde reconstruction, 160</td>
<td></td>
</tr>
<tr>
<td>retro-peritoneal haematoma, 179 classification, 180 revascularisation, 239 critical limb ischaemia, 185 femoral embolectomy, 53, see also thrombectomy rhadomyolysis, 56, see also compartment syndrome</td>
<td></td>
</tr>
<tr>
<td>Roos test, 148</td>
<td></td>
</tr>
<tr>
<td>RP, see Raynaud's phenomenon</td>
<td></td>
</tr>
<tr>
<td>RRT, see renal replacement therapy</td>
<td></td>
</tr>
<tr>
<td>RS, see secondary Raynaud's syndrome</td>
<td></td>
</tr>
<tr>
<td>rTPA, see recombinant tissue plasminogen activator</td>
<td></td>
</tr>
<tr>
<td>saccular aneurysm, 117, 240 saphenofemoral junction ligation, 213 saphenopopliteal junction ligation, 213 saphenous vein stripping, 213 SC, see subcutaneously sciatic artery aneurysm, 25 sclerostats, 250, 251 ethanol, 251 sclerotherapy, 250 technique, 252 secondary Raynaud's syndrome (RS), 255 associated disorders, 257 sensory neuropathy, 69 sepsis, 287, see also gangrene SFA stenting, 81 &quot;bail out&quot; procedure, 82 Shamblin classification, 6 'Silk Road' disease, see Bechet's disease sitophobia, 156 smoking cessation effectiveness, 41 nicotine replacement therapy, 40 pharmacotherapy, 44 recommendations, 39, 40 spinal canal claudication, 59 spinal canal stenosis, 61 Stanford classification, 111 dissections types, 110 statin therapy AAA, 97 anti-inflammatory effects, 43 atherosclerotic plaque, 278</td>
<td></td>
</tr>
</tbody>
</table>
cholesterol reduction vs. events, 43
perioperative cardiac events, 44
stenotic lesions, 158
stent, 81
balloon expandable, 81
self-expanding, 81
stenot graft, 83
infected aortic, 233
uses, 83
stent graft, 83
infected aortic, 233
uses, 83
streptokinase, 74
stroke, 136
asymptomatic stenoses
detection, 137
carotid bifurcation, 137
carotid territory symptoms,
137
carotid territory, causes of,
137
CEMRA and CTA, 138
duplex ultrasound, 138
investigations, 138
management, 138
risk factors, 137
sub-bandage pressure, 30
subclavian occlusive disease
cause, 142
clinical features, 143
indications, 143
investigations, 143
management, 143
subcoracoid space, 146
subcutaneous curettage, 154
sub-intimal angioplasty, 66, 79
suprarenal aneurysms, 104
swelling, 152
compensatory, 154,
see also hyperhidrosis
sympathectomy, 154, 261
chemical, 155
thermocoagulation, 155
systemic inflammatory
syndrome, 132
TA, see Takayasu arteritis
TAAA, see thoracoabdominal
aortic aneurysm
Takayasu arteritis (TA), 19,
133, 262
diagnostic criteria, 262
high dose steroid therapy,
133
immuno-suppressive agents,
134
inflammatory process, 133
investigation, 262
lab investigations, 134
modified Ishikawa
classification, 263
presentation, 262
prognosis, 134
surgical revascularization,
134
symptoms, 133
systemic inflammatory
response, 134
treatment, 263
vascular insufficiency, 134
TASC, see Transatlantic
Inter-Society Consensus
guidelines
TBI, see toe-brachial index
teleangiectasia, see hyphenweb
varices
temporal arteritis, 19,
see also giant cell arteritis
thoracic outlet, 147
thoracic outlet syndrome
(TOS), 146
anatomical factors, 147
arterial, 149
causes, 147
channels, 146
clinical syndromes, 147
investigations, 150
neurogenic, 148
venous, 149
thoracic vascular injuries, 176
diagnosis, 176
investigations, 176
management, 177
thoracoabdominal aortic
aneurysm (TAAA)
blue toe syndrome, 100
causes, 99
complication reduction, 105,
106
complications and adjuncts,
104
CPX testing, 102
Crawford classification, 100
CT angiogram, 100
GI tract risk reduction, 106
intraoperative hepatic, 104
laparotomy, 100
management, 101
open repair results, 105
preoperative assessment, 102
renal and hepatic function,
102
stress echocardiography, 101
type I, 102
type II, 102
type IV, 104
thrombectomy, 227
thromboangiitis obliterans,
see Buerger’s disease
thrombolysis, 227
advantages, 55
complications, 55
contraindications, 55, 75
distal embolization, 75
intra arterial, 54
intra operative, 54
low dose heparin
administration, 74
pharmacological thrombus
dissolution, 74
pre-requisites, 75
regimes, 75
risks, 75
rTPA, 74
streptokinase, 74
thrombolytic agents, 74
urokinase, 74
thrombophilia, 221–4
thrombophlebitis, 206
thrombosis, 51
acute, 124
chronic, 124
graft occlusion, 54
predictors, 127
spontaneous, 127
treatment, 52,
see also arterial
occlusion
through-knee amputation,
190
TIA, see transient ischaemic
attack
toe amputation, 189
toe pressure, 61
toe-brachial index (TBI)
TOS, see thoracic outlet
syndrome
total parenteral nutrition
(TPN), 286
TPN, see total parenteral
nutrition
Transatlantic Inter-Society
Consensus (TASC)
guidelines, 84
lesions types, 84
patient’s comorbidities, 84
transient ischaemic attack
(TIA), 136
transmetatarsal amputation, 189

treadmill walking, 61

truncal varices, 208

UFH, see unfractionated heparin.

UK Small Aneurysm Trial (UKSAT), 91

UKSAT, see UK Small Aneurysm Trial.

unfractionated heparin (UFH), 224

DVT treatment, 224–6

upper limb amputation, 191

urokinase, 74

vagus nerve, 15

varicose veins, 26

aetiology, 205

asymptomatic, 206

clinical examination, 27

clinical features, 206, 208

epidemiology, 204

investigations, 210

recurrent, 214

risk factors, 205

secondary causes, 29

symptomatic, 207

thrombophlebitis, 206

treatment, 213

treatment complications, 214, 215

vascular access, 288

arterio-venous access grafts, 293

arterio-venous fistula, 292

AV grafts, 295

AVF, 292, 294, 295

care after placement, 294

central venous catheters, 293, 296

failure management, 296

operating techniques, 294

placement diagnosis’ need, 289

procedures, 291

RRT commencement, 290

service organisation, 289

stenosis, 294

surveillance, 295

thril detection, 294

types, 291

vascular anomalies, 20

vascular injury

criteria for emergency operation, 173

limb, 174

limb distal vessel injury, 176, see also abdominal vascular injuries, carotid artery injury, iatrogenic vascular injuries, limb distal vessel injury, limb vascular injury, thoracic vascular injuries, vertebral artery injuries

vascular malformations, 20

arteriovenous malformations, 21

capillary malformation, 20

fast-flow, 20

investigations, 20

lymphatic malformations, 21

slow-flow, 20

syndromes, 23

venous malformations, 20, see also congenital vascular malformations

vascular steal syndrome, 296

vascular trauma, 172

vasculitides, 19, 254, 262

Buerger's disease, 266

GCA, 264

TA, 263

vasospasm, see Raynaud's phenomenon

VDU, see visceral duplex ultrasound

vena caval filters, 227–9

venography, 209

contrast venography, 209

CTV, 209

MRV, 209

venous claudication, 61

causes, 218

symptoms, 216, see also intermittent claudication

venous incompetence, 26

venous malformations

AVM, 21

cavernous haemangiomas, 20

slow-flow lesions, 20

varicography, 209

venous thromboembolism (VTE), 220

prophylaxis, 225–11

venous TOS (VTOS), 149

Paget-Schroetter syndrome, 149

rib resection, 150, see also arterial TOS, neurogenic TOS

venous ulceration, 28, 218

clinical assessment, 28

management, 30

sub-bandage pressure, 30

vertebral artery injuries, 179

vertebral discitis, 87

vertebral occlusive disease, 143

investigations, 144

pathology, 144

prognosis, 144

symptoms, 144

treatment methods, 144

‘vibration white finger’, see Raynaud’s phenomenon

Virchow triad, 220

visceral duplex ultrasound (VDU)

chronic mesenteric ischaemia, 157

limitations, 158

von Willebrand factor (VWF), 256

VTE, see venous thromboembolism.

VTOS, see venous TOS

VWF, see von Willebrand factor

walking distance, 65

exercise benefits, 65

vasoactive drugs, 65

warfarin

DVT, 225

warfarin, 278

watershed region, 166

white cell trapping hypothesis, 216

ximelagatran, 226